Why Antibiotics Are Used in HS — and What They Actually Do
Antibiotics became a standard part of HS management because HS lesions — particularly abscesses — contain bacteria, and because antibiotics often reduce acute inflammation and provide short-term symptom relief. This observation created a reasonable working hypothesis: if bacteria are present and antibiotics help, then bacterial infection must be a primary driver of HS.
The evidence has gradually complicated this picture. The bacteria found in HS lesions are, in most cases, commensal organisms — species that normally live on the skin surface without causing disease. They are not external pathogens introduced through a wound or contact with an infected source. They are organisms that have proliferated within the closed, nutrient-rich environment of a ruptured follicle — a secondary event, not the initiating cause. The follicle ruptured because of internal inflammatory and structural processes that had nothing to do with those bacteria. The bacteria arrived after the environment was created for them, not before.
Antibiotics reduce the bacterial burden and the acute inflammatory response. What they do not do is address why the follicle occluded, why the internal inflammatory environment made that occlusion likely, or why the same process will repeat at the same location when the antibiotic course ends. The bacterial component of HS is real; it is simply not the primary driver — and treating it as if it were leads to a predictable pattern of escalation.
The Escalation Pattern — What It Looks Like
The antibiotic escalation pattern in HS is well documented and widely experienced. It typically follows this sequence:
Phase 1 — Initial response: A short course of a single antibiotic produces meaningful symptom relief. Flares resolve more quickly; intervals between episodes seem manageable.
Phase 2 — Diminishing returns: The same antibiotic requires longer courses to achieve the same result. Single-antibiotic courses begin to fail; combination therapy is introduced. Relief is partial or shorter-lived than before.
Phase 3 — Dependence without control: Antibiotics are required continuously to prevent rapid flaring, but no longer prevent it — they only delay or reduce it. The patient is experiencing antibiotic dependence alongside worsening disease. New sites appear. The disease is progressing.
Most patients who have lived with HS for more than a few years recognise this sequence. What they are less often told is what it means.
"When a condition keeps recurring, it usually follows an underlying pattern that needs to be understood and addressed — not suppressed."
What the Escalation Signal Is Communicating
Antibiotic escalation in HS communicates three things clearly:
First, the internal drivers of HS are not being addressed. The bacterial component — which antibiotics can reach — is being managed, partially and temporarily. The gut dysfunction, hormonal imbalance, and immune dysregulation that are sustaining the inflammatory environment — which antibiotics cannot reach — are continuing uncorrected. Each month that passes with the internal drivers active is a month in which the disease becomes more structurally established.
Second, the gut microbiome is being progressively disrupted. Prolonged antibiotic use — particularly broad-spectrum courses used in HS management — significantly alters the gut microbial community. This disruption worsens the very gut dysfunction that is sustaining the HS cycle: a dysbiotic gut generates more inflammatory material, which amplifies the systemic inflammatory baseline, which makes HS more active. Antibiotic escalation for HS may be making the underlying condition worse by one of the mechanisms it is leaving untreated.
Third, the window for effective internal correction is narrowing. Each stage of HS progression — from episodic to chronic, from single-site to multi-site, from nodular to sinus-tract-forming — represents a deeper structural embedding of the disease. Internal correction is possible at every stage, but it is more complex, takes longer, and produces less complete tissue recovery at later stages. Antibiotic escalation is a signal that the disease is progressing toward those later stages.
What Happens to the Gut
The gut consequences of long-term antibiotic use in HS deserve specific attention, because they create a feedback loop that is clinically important and rarely discussed explicitly with patients.
The gut microbiome takes months to years to establish a stable, diverse community of organisms. A single course of broad-spectrum antibiotics can significantly reduce microbial diversity — an effect that may partially recover over weeks but often does not fully restore pre-treatment diversity. Repeated courses produce cumulative disruption. By the time a patient has been through two to three years of antibiotic management for HS, their gut microbiome is typically substantially different from its pre-treatment state — and substantially more dysbiotic.
A more dysbiotic gut generates a stronger systemic inflammatory signal. A stronger systemic inflammatory signal creates a more active internal environment for HS. The patient requires stronger antibiotics to manage a disease that is being made more internally active by the antibiotics being used to manage it. This is not a universal outcome — individual gut resilience varies — but it is a clinically observed pattern that helps explain why some patients experience rapid escalation while receiving apparently appropriate antibiotic management.
Ayurvedic medicine recognises the gut as the primary site of health and disease — the state of digestive function (Agni) is understood to determine the quality of all subsequent biological processes. When digestive function is disrupted — whether by disease, inappropriate food, or treatments that damage the digestive environment — the entire system is compromised. Antibiotic-related gut disruption aligns closely with this understanding: it impairs the body's primary regulatory mechanism, generating a cascade of downstream consequences including amplified inflammatory activity. Restoring gut function is not an optional adjunct to HS treatment in this framework — it is the primary intervention.
The Antibiotic Dependence Trap
Perhaps the most clinically difficult aspect of antibiotic escalation in HS is antibiotic dependence — the state in which the disease flares acutely when antibiotics are stopped, even when it was not well controlled while they were continued. This dependence creates a practical dilemma: stopping antibiotics produces an immediate worsening that feels like a treatment failure, while continuing them produces progressive gut disruption and diminishing disease control.
Antibiotic dependence develops because the antibiotics have been partially suppressing the acute bacterial component of HS episodes while the internal drivers have continued to intensify uncorrected. When the antibiotic is removed, the suppression is lifted on a disease that is now more internally active than when the antibiotics were started. The rebound is not evidence that antibiotics are necessary — it is evidence of how much the disease has progressed during the antibiotic management period.
This trap is not easy to exit, and it should not be exited abruptly. But it can be exited — through a structured transition in which internal correction is initiated and gradually reduces the dependence on antibiotic suppression. This transition requires patience and a clear understanding of what is happening internally, not simply a decision to stop taking antibiotics.
What the Evidence Base Actually Shows
The evidence base for long-term antibiotic use in HS is notably limited. Studies consistently show short-term benefit in reducing inflammatory markers and lesion counts during treatment. Long-term outcome data — what happens to patients five or ten years into antibiotic management — is sparse and generally not encouraging. Recurrence after cessation is near-universal. Disease progression during treatment is documented. The gut consequences of long-term use are rarely examined in HS-specific research but are well established in the broader literature on antibiotic ecology.
This is not an argument against all antibiotic use in HS. In acute, severe flares, short-course antibiotics serve a real purpose in reducing acute bacterial burden and preventing local spread. The argument is against long-term antibiotic management as a substitute for addressing the internal drivers that are sustaining the disease — because the evidence does not support that substitution as producing meaningful long-term benefit, and the consequences of the substitution are clinically significant.
"Unless the underlying causes are addressed, the condition may continue to recur despite treatment."
Reading the Signal — What to Do With It
When antibiotic escalation is occurring, the signal it sends is clear: the treatment approach needs to be expanded to address what antibiotics cannot reach. This means evaluating the gut, the hormonal system, the metabolic state, and the immune regulatory environment — and initiating correction of whichever of these is actively sustaining the disease in the individual patient.
It also means reconsidering the role of antibiotics within a broader treatment framework rather than as the primary intervention. Used selectively — in acute situations where bacterial burden is contributing meaningfully to the clinical picture — antibiotics remain a useful tool. Used as continuous long-term management in the absence of internal correction, they are a tool being asked to perform a task for which they were not designed.
The antibiotic escalation signal is not a reason for despair or frustration — though both are understandable responses in patients who have been through this cycle. It is clinical information pointing toward what needs to change. What it changes toward is a more complete understanding of what HS is and what it requires.